Heparin - Market Insights, Competitive Landscape, and Market Forecast - 2030

Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising cases of cardiovascular disorders and the growing demand for blood component transfusion globally.

The Heparin market was valued at USD 9.31 billion in 2023, growing at a CAGR of 7.05% during the forecast period from 2024 to 2030 to reach USD 14.96 billion by 2030. The demand for Heparin is primarily being boosted owing to the rising cases of cardiovascular disorders, the growing number of risk factors for cancers such as smoking, exposure to radiation, faulty lifestyle, and others, rising research and developmental activities by global market players, during the forecast period from 2024-2030.

Heparin Market Dynamics

One of the key factors influencing the growth of the heparin market is the rising number of cardiovascular disorders such as cardiac arrhythmias, atrial fibrillation, and coronary heart disease, among others globally.

According to data provided by the British Heart Foundation 2024, around 620 million people are living with heart and circulatory diseases across the world. Additionally, the same source stated that globally it's estimated that 1 in 13 people are living with a heart or circulatory disease. As per data by the British Heart Foundation UK Factsheet 2024, it was estimated that around 7.6 million people live with heart and circulatory diseases in the UK on average annually.

Moreover, as per the study titled "Status of Cardiovascular Diseases in China (2023)" it was estimated that approximately 330 million people in China were affected by CVDs including 11.39 million from coronary heart disease, 5 million from pulmonary heart disease, and 2.5 million from rheumatic heart disease in 2022. Also, as per the recent study published in "The Lancet Global Health," it was stated that around 0.44 million to 3.37 million people in India are affected by rheumatic heart disease every year on average.

In the treatment of unstable coronary artery disease, therapeutic-dose unfractionated heparin is effective in reducing adverse ischemic outcomes, including death and myocardial infarction. Also, intravenous heparin is efficient in avoiding future cardiac events following an episode of unstable coronary artery disease (CAD). Heparin such as low-molecular-weight heparin has similar antithrombotic characteristics, which can also be administered subcutaneously and is suited for long-term treatment.

As cardiovascular disorders become more prevalent, the adoption of heparin is expected to increase, and there will be a greater need for the accurate treatment of such disorders. Thus, owing to all the above-mentioned factors, the adoption of heparin is expected to increase, which would propel the market for heparin during the forecast period from 2024 to 2030.

However, potential and fatal side effects associated with the use of heparin, and the availability of alternative methods of anticoagulation, among others may act as significant restraints that are expected to limit the growth of the heparin market during the forecast period.

Heparin Market Segment Analysis:

Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of the heparin market, the coronary artery disease category is estimated to amass a significant revenue share in the Heparin market in 2023. This can be attributed to the growing burden of coronary heart diseases worldwide, and the role of heparin in the management of coronary heart diseases during the given forecast period.

According to the American Heart Association 2022, globally, about 244.1 million people were living with coronary heart disease in 2020. As per the same source, North Africa, the Middle East, Central and South Asia, and Eastern Europe had the highest prevalence rates of coronary (ischemic) heart disease in the world in 2020.

In countries such as Australia, in 2020-2021, an estimated 571,000 Australians aged 18 and over (2.9% of the adult population) had Coronary heart disease (CHD), based on data from the Australian Bureau of Statistics 2020-21 National Health Survey. The prevalence of CHD increased rapidly with age, affecting around 1 in 9 (11%) adults aged 75 and over, in 2020-2021.

Heparins such as low-molecular-weight heparins have a predictable pharmacokinetic profile, high bioavailability, and long plasma half-life, all of which result in effective levels of anticoagulant activity after subcutaneous administration. In the treatment of unstable coronary artery disease, heparin is found to be effective in reducing adverse ischemic outcomes, including death and myocardial infarction. In addition, low-molecular-weight heparins might also have the potential to improve the efficacy and safety of antithrombotic therapy in the management of unstable coronary artery disease.

Hence, owing to all the aforementioned factors, the market will experience an increased demand for heparin in the coronary artery disease category, thus driving the growth of the overall heparin market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall heparin market:

North America is expected to account for the highest proportion of the heparin market in 2023, out of all regions. This is due to the growing prevalence of cardiovascular disorders in the region. Additionally, increasing risk factors associated with cardiovascular disorders, the presence of robust research and development initiatives, and a highly viable market in terms of product development, and launches are some of the key factors driving the growth of the heparin market in North America.

As per the data provided American Heart Association 2020, it was estimated that at least 3 to 6 million people are suffering from atrial fibrillation which is expected to reach 6 to 16 million by the year 2050 in the United States. Further, according to the data provided by the Centers for Disease Control and Prevention 2023, it was estimated that around 60 million women (44%), are living with some form of heart disease in the United States.

Thus, the increasing prevalence of cardiovascular disorders will create a need for the treatment of such cardiovascular disorders, thus contributing to the growing market demand for heparin in the United States, which will in return propel the market for heparin in North America.

Moreover, the rising number of heparin product launches is also expected to boost the heparin market in the North America region. For example, in February 2024, B. Braun Medical Inc. announced the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags. The launch reaffirmed B. Braun's commitment to improving the security of supply by manufacturing pharmaceuticals in the United States from its Irvine, CA, facility.

Due to the high patient population base in North America, the adoption of heparin for treatment purposes is expected to increase the market demand for heparin in the upcoming years. Thus, due to the interplay of all the above-mentioned factors, it will lead to an increase in the North America heparin market growth during the forecast period from 2024 to 2030.

Heparin Market Key Players:

Some of the key market players operating in the Heparin market include Pfizer Inc., Leo Pharma A/S, Dr. Reddy's Laboratories Ltd., GSK plc., Sanofi, B. Braun Melsungen AG, Aspen Holdings, Fresenius SE & Co. KGaA, Novartis AG, Baxter, and others.

Recent Developmental Activities In the Heparin Market:

• In November 2023, the FDA approved a taurolidine plus heparin (DefenCath(R)) catheter lock solution to reduce catheter-related bloodstream infections in patients receiving maintenance hemodialysis via a central venous catheter (CVC).
• In February 2022, Techdow USA Inc. announced the launch of its Heparin Sodium Injection, USP in the US market.
• In January 2022, the Ohio biotechnology firm Optimvia Pharmaceuticals developed a cost-effective synthetic method to produce large quantities of heparin, used to make common blood thinner, also striking a deal with the synthetic biology firm Ginkgo Bioworks to scale the process up.

Key Takeaways From the Heparin Market Report Study:

• Market size analysis for current heparin market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key offerings, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the heparin market.
• Various opportunities available for the other competitors in the heparin market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current heparin market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for heparin market growth in the coming future?

Target Audience Who Can be Benefited From This Heparin Market Report Study

• Heparin providers
• Public and Private Corporate companies
• Heparin-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Providers dealing in heparin
• Various corporates who want to know more about the heparin market and the latest offerings in the heparin market.

Frequently Asked Questions for the Heparin Market:

1. What are Heparin?

Heparin is a medication and a naturally occurring glycosaminoglycan. Heparin is a blood anticoagulant that increases the activity of antithrombin, used in the treatment of heart attacks and unstable angina.

2. What is the market for Heparin?

The Heparin market was valued at USD 9.31 billion in 2023, growing at a CAGR of 7.05% during the forecast period from 2024 to 2030 to reach USD 14.96 billion by 2030.

3. What are the drivers for the Heparin market?

The Heparin market is slated to witness prosperity owing to the rising cases of cardiovascular disorders, the growing number of risk factors for cancers such as smoking, exposure to radiation, faulty lifestyle, and others, rising research and developmental activities by global market players, during the forecast period from 2024-2030.

4. Who are the key players operating in the Heparin market?

Some of the key market players operating in the Heparin market include Pfizer Inc., Leo Pharma A/S, Dr. Reddy's Laboratories Ltd., GSK plc., Sanofi, B. Braun Melsungen AG, Aspen Holdings, Fresenius SE & Co. KGaA, Novartis AG, Baxter, and others.

5. Which region has the highest share in the Heparin market?

North America is expected to dominate the overall Heparin market during the forecast period from 2024 to 2030. This is due to the growing prevalence of cardiovascular disorders in the region. Additionally, increasing risk factors associated with cardiovascular disorders, the presence of robust research and development initiatives, and a highly viable market in terms of product development, and launches are some of the key factors driving the growth of the heparin market in North America.